The ‘LifeSciencesUK’ is expected to allow biotechnology, pharmaceuticals, medical devices and diagnostics sectors to jointly funtion smoothly to better investment environment in the UK, reported Pharmacy Europe.
‘LifeSciencesUK’ aims to facilitate collaboration with industry across departments, specifically that belongs to business and health, as well as to academia, patient groups, the media and other stakeholders.
Pharmacy Europe has quoted ABHI CEO Peter Ellingworth as saying that LifeSciencesUK will complement and support work being done across government by various teams concerned with the life sciences industries and health policy.
Pharmacy Europe has quoted BIA CEO Nigel Gaymond as saying that the initiative will enable them to be more effective in creating a supportive environment for the industry, which will ultimately result in greater healthcare benefits for patients.
BIVDA director general Doris-Ann Williams said in vitro diagnostics has a central role to play in helping to turn the UK’s inherent strengths in life sciences into economic growth, as well as realising improved outcomes and cost-effectiveness for the NHS, reported Pharmacy Europe.
